SCHEMBL3867656

SCHEMBL3867656

C#CCNc1nc(Nc2ccc(N)cc2)ncc1Br

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 7/20 0.77
CDK2 P24941 6/20 0.77
CCNB1 P14635 3/20 0.77
CCNE1 P24864 3/20 0.77
CA2 P00918 4/20 0.74
IGF1R P08069 3/20 0.52
STK17A Q9UEE5 2/20 0.52
STK17B O94768 1/20 0.52
SYK P43405 2/20 0.51
KDR P35968 5/20 0.46
GSK3B P49841 1/20 0.46
PTK2 Q05397 1/20 0.45
CDK4 P11802 2/20 0.45
CDK7 P50613 2/20 0.45
CDK9 P50750 2/20 0.45
CCNT1 O60563 1/20 0.45
CCND1 P24385 1/20 0.45
CCNH P51946 1/20 0.45
CHEK1 O14757 1/20 0.45
NTRK2 Q16620 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13897507 0.88 CDK1 (0.70) CDK1CDK2CCNB1CCNE1CA2
SCHEMBL13897496 0.88 CDK1 (0.73) CDK1CDK2CCNB1CCNE1CA2
SCHEMBL4022058 0.87 CDK1 (0.77) CDK1CDK2CCNB1CCNE1CA2
SCHEMBL4063385 0.85 CA2 (1.00) CDK1CDK2CCNB1CCNE1CA2
SCHEMBL4027058 0.85 CDK1 (0.73) CDK1CDK2CCNB1CCNE1CA2
SCHEMBL13897686 0.85 CDK2 (0.73) CDK1CDK2CCNB1CCNE1CA2
SCHEMBL14355372 0.85 CDK1 (0.73) CDK1CDK2CCNB1CCNE1CA2
SCHEMBL13901274 0.85 CDK1 (0.55) CDK1CDK2CCNB1CCNE1CA2
SCHEMBL3966386 0.84 CA2 (0.71) CDK1CDK2CCNB1CCNE1CA2
SCHEMBL4019758 0.83 CDK1 (0.70) CDK1CDK2CCNB1CCNE1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 US disclosed
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 US disclosed
US-7504410-B2 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 2009-03-17 US disclosed
CN-1717396-A Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents SCHERING AG (DE) 2006-01-04 CN disclosed
EP-1565446-A1 CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2005-08-24 EP disclosed
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-09-23 US disclosed
WO-2004048343-A1 CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS SCHERING AKTIENGESELLSCHAFT (DE) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186118-A1 Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents DCK, PDPK1, DTYMK CDK1 237/4885CDK2 105/4885CCNB1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.